Staff Reports
The big news this week at the Food and Drug Administration isn’t a new rule or a blockbuster drug approval. It’s a change in the person in charge. Commissioner Marty Makary stepped down, and Kyle Diamantas — the agency’s deputy commissioner for human foods — is now the Acting Commissioner of Food and Drugs. That personnel move has conservatives and industry watchers claiming a cultural shift at the FDA toward efficiency, food-safety focus, and faster drug reviews. We should pay attention — and not hand the government more applause before seeing results.
New boss, new tone: what this leadership flip means
Make no mistake: leadership matters at the FDA. Diamantas comes from inside the agency’s food shop, not from a big pharmaceutical hedge fund. His background as the former deputy commissioner for human foods suggests he will put food safety and nutrition front and center while keeping the agency focused on getting things done. Senators like Roger Marshall are already praising the move, saying the agency needs to stop letting industry write its own safety rules. That is a sensible point, and it is why a food-first commissioner is worth watching.
Food safety and additives — real priorities, not headline-grabbing theater
Under Diamantas, expect renewed attention to food additives, ultra-processed foods, and the long list of chemicals currently approved by the old GRAS (Generally Recognized as Safe) process. The FDA has already signaled moves to remove certain petroleum-based dyes and reassess other additives. If the agency actually enforces safety instead of outsourcing judgment to manufacturers, American families will be better off. Just don’t confuse regulatory vigor with nanny-state micromanagement — Americans still deserve freedom to choose their food without unnecessary government shrieks.
Drug reviews, rare diseases, and the promise of efficiency
One reason this change matters is Makary’s push for faster, more efficient drug reviews. Diamantas inherits those programs — including AI-assisted review pilots — and people are asking whether the FDA will keep moving toward quicker approvals, especially for rare-disease treatments. Conservatives should cheer faster, smarter review when it helps patients get access without sacrificing safety. As critics note, drug development costs are huge because of high failure rates. Finding ways to detect failures earlier and cut red tape will reduce costs and help patients, not Big Pharma’s profit margins alone.
Watch the revolving door and keep the pressure on
Still, let’s be realistic. Efficiency is easy to promise and harder to deliver. The agency must be guarded against the same old problem: the revolving door between regulators and big industry. Former FDA analysts warn that many past commissioners left for lucrative private-sector jobs — a pattern that corrupts incentives. Diamantas needs oversight, not a victory lap. Keep an eye on internal shuffles, like the replacement of his old deputy slot, and on whether the agency preserves scientific rigor while trimming the red tape. If he can do that, this leadership change could be the shakeup conservatives said they wanted. If not, it will be more theater for the cameras.
